Kairos Pharma partners with Bayer to test ENV-105 with Xofigo in metastatic prostate cancer

Kairos Pharma, Ltd.

KAPA

0.00

Kairos Pharma entered a strategic collaboration with Bayer to test ENV-105 with Bayer’s Xofigo in metastatic castration-resistant prostate cancer with bone involvement.
Program targets loss of response to standard therapies; ENV-105 is positioned as a CD105/BMP signaling inhibitor to re-sensitize tumors to radiation-based treatment.
Xofigo is FDA-approved for mCRPC with symptomatic bone metastases; Bayer is also running combination studies including Phase III PEACE-3.
Kairos cited Phase 2 interim data for ENV-105 in advanced prostate cancer showing median progression-free survival of more than 13 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722029697) on July 22, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.